Linezolid

Linezolid, the active ingredient in Linezolid, is a Oxazolidinone presented as a Injection for Intravenous use. It treats complicated skin and soft tissue infections, community‑acquired bacterial pneumonia, nosocomial pneumonia, methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) infections in adult patients.

GNH USA supplies Linezolid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibiotic used for serious Gram‑positive bacterial infections.

- Complicated skin and soft tissue infections: provides bacterial eradication and clinical cure in adults. - Community‑acquired bacterial pneumonia: improves respiratory outcomes against susceptible pathogens. - Nosocomial pneumonia: effective for hospital‑acquired lung infections caused by resistant Gram‑positive organisms. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers an alternative to vancomycin for skin and systemic disease. - Vancomycin‑resistant Enterococcus (VRE) infections: achieves bacterial clearance where other agents fail.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring during therapy. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Rash: skin erythema or pruritus. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Anemia: reduction in red blood cell levels. - Peripheral neuropathy: sensory disturbances with prolonged use. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Severe hypotension: abrupt blood pressure decline during infusion.

When prescribing Linezolid, clinicians should observe several safety measures.

- Monitor blood counts: watch for thrombocytopenia and anemia. - Assess renal and hepatic function: adjust therapy if organ impairment is present. - Avoid serotonergic drugs: concurrent use can precipitate serotonin syndrome. - Caution with myelosuppressive agents: increased risk of bone‑marrow suppression. - Use with care in patients with a history of peripheral neuropathy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Serotonergic agents (SSRIs, SNRIs, MAO inhibitors): may trigger serotonin syndrome. - Rifampin: reduces linezolid plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: increased risk of bleeding due to platelet effects. - Warfarin: potential alteration of anticoagulant response. - Antidiabetic drugs: enhanced hypoglycemic effect. - Other myelosuppressive agents: additive bone‑marrow toxicity. - Sympathomimetic agents (pseudoephedrine, decongestants): may cause hypertensive reactions.